Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sub-study to the A2M Study to Evaluate the Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in the A2M Study

NCT05896761 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT05896761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05896761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sub-study to the A2M Study to Evaluate the Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in the A2M Study
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
October 28, 2021
Completion date
August 23, 2022
Enrollment
118 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus type 1 (hiv-1)